{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:10:38Z","timestamp":1790521838964,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previous studies showed a low-grade enterovirus infection in the pancreatic islets of patients with newly diagnosed type 1 diabetes (T1D). In the Diabetes Virus Detection (DiViD) Intervention, a phase 2, placebo-controlled, randomized, parallel group, double-blind trial, 96 children and adolescents (aged 6\u201315\u2009years) with new-onset T1D received antiviral treatment with pleconaril and ribavirin (<jats:italic>n<\/jats:italic>\u2009=\u200947) or placebo (<jats:italic>n<\/jats:italic>\u2009=\u200949) for 6\u2009months, with the aim of preserving \u03b2 cell function. The primary endpoint was the mean stimulated C-peptide area under the curve (AUC) 12\u2009months after the initiation of treatment (less than 3\u2009weeks after diagnosis) using a mixed linear model. The model used longitudinal log-transformed serum C-peptide AUCs at baseline, at 3\u2009months, 6\u2009months and 1\u2009year. The primary endpoint was met with the serum C-peptide AUC being higher in the pleconaril and ribavirin treatment group compared to the placebo group at 12\u2009months (average marginal effect\u2009=\u20090.057 in the linear mixed model; 95% confidence interval\u2009=\u20090.004\u20130.11,<jats:italic>P<\/jats:italic>\u2009=\u20090.037). The treatment was well tolerated. The results show that antiviral treatment may preserve residual insulin production in children and adolescent with new-onset T1D. This provides a rationale for further evaluating antiviral strategies in the prevention and treatment of T1D. European Union Drug Regulating Authorities Clinical Trials identifier:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2015-003350-41\">2015-003350-41<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41591-023-02576-1","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T23:02:32Z","timestamp":1696374152000},"page":"2902-2908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial"],"prefix":"10.1038","volume":"29","author":[{"given":"Lars","family":"Krogvold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1420-3359","authenticated-orcid":false,"given":"Ida Maria","family":"Mynarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Ponzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freja Barrett","family":"M\u00f8rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Witzner","family":"Hessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Roald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Lindblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Westman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Hy\u00f6ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-5234","authenticated-orcid":false,"given":"Johnny","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian F.","family":"Hanssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-9899","authenticated-orcid":false,"given":"Knut","family":"Dahl-J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"2576_CR1","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2337\/dc14-1140","volume":"37","author":"JL Chiang","year":"2014","unstructured":"Chiang, J. L., Kirkman, M. S., Laffel, L. M. & Peters, A. L. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37, 2034\u20132054 (2014).","journal-title":"Diabetes Care"},{"key":"2576_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","volume":"392","author":"A Rawshani","year":"2018","unstructured":"Rawshani, A. et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 392, 477\u2013486 (2018).","journal-title":"Lancet"},{"key":"2576_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2337\/dc15-0144","volume":"38","author":"MA Atkinson","year":"2015","unstructured":"Atkinson, M. A., von Herrath, M., Powers, A. C. & Clare-Salzler, M. Current concepts on the pathogenesis of type 1 diabetes\u2014considerations for attempts to prevent and reverse the disease. Diabetes Care 38, 979\u2013988 (2015).","journal-title":"Diabetes Care"},{"key":"2576_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrendo.2010.27","volume":"6","author":"D Hober","year":"2010","unstructured":"Hober, D. & Sauter, P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 6, 279\u2013289 (2010).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2576_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s001250051614","volume":"44","author":"HS Jun","year":"2001","unstructured":"Jun, H. S. & Yoon, J. W. The role of viruses in type I diabetes: two distinct cellular and molecular pathogenic mechanisms of virus-induced diabetes in animals. Diabetologia 44, 271\u2013285 (2001).","journal-title":"Diabetologia"},{"key":"2576_CR6","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41591-019-0667-0","volume":"25","author":"K Vehik","year":"2019","unstructured":"Vehik, K. et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat. Med. 25, 1865\u20131872 (2019).","journal-title":"Nat. Med."},{"key":"2576_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00431-016-2725-7","volume":"175","author":"SC de Crom","year":"2016","unstructured":"de Crom, S. C., Rossen, J. W., van Furth, A. M. & Obihara, C. C. Enterovirus and parechovirus infection in children: a brief overview. Eur. J. Pediatr. 175, 1023\u20131029 (2016).","journal-title":"Eur. J. Pediatr."},{"key":"2576_CR8","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964\u20131974 (2015).","journal-title":"Diabetes Care"},{"key":"2576_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2213-8587(23)00122-5","volume":"11","author":"SR Isaacs","year":"2023","unstructured":"Isaacs, S. R. et al. Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol. 11, 578\u2013592 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2576_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2209","volume":"31","author":"CL Faulkner","year":"2021","unstructured":"Faulkner, C. L. et al. The virome in early life and childhood and development of islet autoimmunity and type 1 diabetes: a systematic review and meta-analysis of observational studies. Rev. Med. Virol. 31, 1\u201314 (2021).","journal-title":"Rev. Med. Virol."},{"key":"2576_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00125-012-2745-4","volume":"56","author":"SJ Richardson","year":"2013","unstructured":"Richardson, S. J., Leete, P., Bone, A. J., Foulis, A. K. & Morgan, N. G. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia 56, 185\u2013193 (2013).","journal-title":"Diabetologia"},{"key":"2576_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00125-013-3155-y","volume":"57","author":"L Krogvold","year":"2014","unstructured":"Krogvold, L. et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 57, 841\u2013843 (2014).","journal-title":"Diabetologia"},{"key":"2576_CR13","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-022-05779-2","volume":"65","author":"L Krogvold","year":"2022","unstructured":"Krogvold, L. et al. Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. Diabetologia 65, 2108\u20132120 (2022).","journal-title":"Diabetologia"},{"key":"2576_CR14","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.2337\/db14-1370","volume":"64","author":"L Krogvold","year":"2015","unstructured":"Krogvold, L. et al. Detection of a low-grade enteroviral infection in the islets of Langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes 64, 1682\u20131687 (2015).","journal-title":"Diabetes"},{"key":"2576_CR15","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00125-021-05525-0","volume":"64","author":"S Oikarinen","year":"2021","unstructured":"Oikarinen, S. et al. Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia 64, 2491\u20132501 (2021).","journal-title":"Diabetologia"},{"key":"2576_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1007\/s00125-018-4704-1","volume":"61","author":"E Ifie","year":"2018","unstructured":"Ifie, E. et al. Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia 61, 2344\u20132355 (2018).","journal-title":"Diabetologia"},{"key":"2576_CR17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00125-019-4811-7","volume":"62","author":"JL Dunne","year":"2019","unstructured":"Dunne, J. L. et al. Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia 62, 744\u2013753 (2019).","journal-title":"Diabetologia"},{"key":"2576_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.antiviral.2006.12.001","volume":"74","author":"A-K Berg","year":"2007","unstructured":"Berg, A.-K., Olsson, A., Korsgren, O. & Frisk, G. Antiviral treatment of Coxsackie B virus infection in human pancreatic islets. Antiviral Res. 74, 65\u201371 (2007).","journal-title":"Antiviral Res."},{"key":"2576_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/135965350200700107","volume":"7","author":"FG Hayden","year":"2002","unstructured":"Hayden, F. G. et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antivir. Ther. 7, 53\u201365 (2002).","journal-title":"Antivir. Ther."},{"key":"2576_CR20","doi-asserted-by":"publisher","first-page":"104334","DOI":"10.1016\/j.jcv.2020.104334","volume":"128","author":"A Honkimaa","year":"2020","unstructured":"Honkimaa, A. et al. Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs. J. Clin. Virol. 128, 104334 (2020).","journal-title":"J. Clin. Virol."},{"key":"2576_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jpids\/piv015","volume":"5","author":"MJ Abzug","year":"2016","unstructured":"Abzug, M. J. et al. A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J. Pediatric. Infect. Dis. Soc. 5, 53\u201362 (2016).","journal-title":"J. Pediatric. Infect. Dis. Soc."},{"key":"2576_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/dme.14175","volume":"37","author":"AB Sioofy-Khojine","year":"2020","unstructured":"Sioofy-Khojine, A. B., Honkimaa, A. & Hy\u00f6ty, H. A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Diabet. Med. 37, 1849\u20131853 (2020).","journal-title":"Diabet. Med."},{"key":"2576_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1128\/AAC.24.3.353","volume":"24","author":"JJ Kirsi","year":"1983","unstructured":"Kirsi, J. J. et al. Broad-spectrum antiviral activity of 2-beta-d-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob. Agents Chemother. 24, 353\u2013361 (1983).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2576_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/cells12030453","volume":"12","author":"P Kupke","year":"2023","unstructured":"Kupke, P. et al. Immunomodulation of natural killer cell function by ribavirin involves TYK-2 activation and subsequent increased IFN-\u03b3 secretion in the context of in vitro hepatitis E virus infection. Cells 12, 453 (2023).","journal-title":"Cells"},{"key":"2576_CR25","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/microorganisms8071017","volume":"8","author":"S Geravandi","year":"2020","unstructured":"Geravandi, S., Liu, H. & Maedler, K. Enteroviruses and T1D: is it the virus, the genes or both which cause T1D. Microorganisms 8, 1017 (2020).","journal-title":"Microorganisms"},{"key":"2576_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/vaccines10050770","volume":"10","author":"NM Chapman","year":"2022","unstructured":"Chapman, N. M. Persistent enterovirus infection: little deletions, long infections. Vaccines 10, 770 (2022).","journal-title":"Vaccines"},{"key":"2576_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrendo.2016.30","volume":"12","author":"A Op de Beeck","year":"2016","unstructured":"Op de Beeck, A. & Eizirik, D. L. Viral infections in type 1 diabetes mellitus\u2014why the \u03b2 cells? Nat. Rev. Endocrinol. 12, 263\u2013273 (2016).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2576_CR28","doi-asserted-by":"publisher","first-page":"e06990","DOI":"10.7554\/eLife.06990","volume":"4","author":"L Marroqui","year":"2015","unstructured":"Marroqui, L. et al. Differential cell autonomous responses determine the outcome of coxsackievirus infections in murine pancreatic \u03b1 and \u03b2 cells. eLife 4, e06990 (2015).","journal-title":"eLife"},{"key":"2576_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00125-012-2762-3","volume":"56","author":"DL Eizirik","year":"2013","unstructured":"Eizirik, D. L., Miani, M. & Cardozo, A. K. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 56, 234\u2013241 (2013).","journal-title":"Diabetologia"},{"key":"2576_CR30","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1161\/CIRCULATIONAHA.118.035966","volume":"139","author":"A Bouin","year":"2019","unstructured":"Bouin, A. et al. Enterovirus persistence in cardiac cells of patients with idiopathic dilated cardiomyopathy is linked to 5\u2032 terminal genomic RNA-deleted viral populations with viral-encoded proteinase activities. Circulation 139, 2326\u20132338 (2019).","journal-title":"Circulation"},{"key":"2576_CR31","doi-asserted-by":"publisher","first-page":"l231","DOI":"10.1136\/bmj.l231","volume":"364","author":"CR Kahrs","year":"2019","unstructured":"Kahrs, C. R. et al. Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort. BMJ 364, l231 (2019).","journal-title":"BMJ"},{"key":"2576_CR32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/gutjnl-2019-319809","volume":"69","author":"K Lindfors","year":"2020","unstructured":"Lindfors, K. et al. Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study. Gut 69, 1416\u20131422 (2020).","journal-title":"Gut"},{"key":"2576_CR33","doi-asserted-by":"publisher","first-page":"604529","DOI":"10.3389\/fimmu.2020.604529","volume":"11","author":"M Oikarinen","year":"2021","unstructured":"Oikarinen, M. et al. Enterovirus infections are associated with the development of celiac disease in a birth cohort study. Front. Immunol. 11, 604529 (2021).","journal-title":"Front. Immunol."},{"key":"2576_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.abm7930","volume":"375","author":"WH Robinson","year":"2022","unstructured":"Robinson, W. H. & Steinman, L. Epstein\u2013Barr virus and multiple sclerosis. Science 375, 264\u2013265 (2022).","journal-title":"Science"},{"key":"2576_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/jmv.23476","volume":"85","author":"SS Hammerstad","year":"2013","unstructured":"Hammerstad, S. S. et al. Detection of enterovirus in the thyroid tissue of patients with Graves\u2019 disease. J. Med. Virol. 85, 512\u2013518 (2013).","journal-title":"J. Med. Virol."},{"key":"2576_CR36","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.2337\/db14-1911","volume":"64","author":"L Krogvold","year":"2015","unstructured":"Krogvold, L. et al. Function of isolated pancreatic islets from patients at onset of type 1 diabetes: insulin secretion can be restored after some days in a non-diabetogenic environment in vitro: results from the DiViD study. Diabetes 64, 2506\u20132512 (2015).","journal-title":"Diabetes"},{"key":"2576_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00281-014-0438-4","volume":"36","author":"P In\u2019t Veld","year":"2014","unstructured":"In\u2019t Veld, P. Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin. Immunopathol. 36, 569\u2013579 (2014).","journal-title":"Semin. Immunopathol."},{"key":"2576_CR38","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/hep.27186","volume":"60","author":"MU Mondelli","year":"2014","unstructured":"Mondelli, M. U. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? Hepatology 60, 1126\u20131129 (2014).","journal-title":"Hepatology"},{"key":"2576_CR39","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1089\/dia.2020.0305","volume":"22","author":"LM Jacobsen","year":"2020","unstructured":"Jacobsen, L. M. et al. Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Technol. Ther. 22, 948\u2013953 (2020).","journal-title":"Diabetes Technol. Ther."},{"key":"2576_CR40","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2023.2064","volume":"329","author":"GP Forlenza","year":"2023","unstructured":"Forlenza, G. P. et al. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA 329, 990\u2013999 (2023).","journal-title":"JAMA"},{"key":"2576_CR41","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2337\/dc20-0567","volume":"44","author":"A Jeyam","year":"2021","unstructured":"Jeyam, A. et al. Clinical impact of residual C-peptide secretion in type 1 diabetes on glycemia and microvascular complications. Diabetes Care 44, 390\u2013398 (2021).","journal-title":"Diabetes Care"},{"key":"2576_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hep.510260231","volume":"26","author":"HC Bodenheimer Jr","year":"1997","unstructured":"Bodenheimer, H. C.Jr et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26, 437\u2013477 (1997).","journal-title":"Hepatology"},{"key":"2576_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06259-z","volume":"23","author":"DB Dunger","year":"2022","unstructured":"Dunger, D. B. et al. INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes. Trials 23, 414 (2022).","journal-title":"Trials"},{"key":"2576_CR44","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.2337\/dc07-2451","volume":"31","author":"CJ Greenbaum","year":"2008","unstructured":"Greenbaum, C. J. et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of \u03b2-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31, 1966\u20131971 (2008).","journal-title":"Diabetes Care"},{"key":"2576_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/00365513.2015.1129671","volume":"76","author":"C Brede","year":"2016","unstructured":"Brede, C., Hop, B., J\u00f8rgensen, K. & Skadberg, \u00d8. Measurement of glycated albumin in serum and plasma by LC\u2013MS\/MS. Scand. J. Clin. Lab. Invest. 76, 195\u2013201 (2016).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"2576_CR46","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jcv.2012.11.018","volume":"56","author":"H Honkanen","year":"2013","unstructured":"Honkanen, H. et al. Human enterovirus 71 strains in the background population and in hospital patients in Finland. J. Clin. Virol. 56, 348\u2013353 (2013).","journal-title":"J. Clin. Virol."},{"key":"2576_CR47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/diabetes.53.1.250","volume":"53","author":"JP Palmer","year":"2004","unstructured":"Palmer, J. P. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve \u03b2-cell function: report of an ADA workshop, 21\u201322 October 2001. Diabetes 53, 250\u2013264 (2004).","journal-title":"Diabetes"},{"key":"2576_CR48","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa0804328","volume":"359","author":"J Ludvigsson","year":"2008","unstructured":"Ludvigsson, J. et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359, 1909\u20131920 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2576_CR49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/dmrr.2800","volume":"32","author":"BN Bundy","year":"2016","unstructured":"Bundy, B. N. & Krischer, J. P. A model-based approach to sample size estimation in recent onset type 1 diabetes. Diabetes Metab. Res. Rev. 32, 827\u2013834 (2016).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"2576_CR50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00031305.1980.10483031","volume":"34","author":"SR Searle","year":"1980","unstructured":"Searle, S. R., Speed, F. M. & Milliken, G. A. Population marginal means in the linear model: an alternative to least squares means. Am. Stat. 34, 216\u2013221 (1980).","journal-title":"Am. Stat."},{"key":"2576_CR51","doi-asserted-by":"publisher","first-page":"e013096","DOI":"10.1136\/bmjopen-2016-013096","volume":"6","author":"CJ Coffman","year":"2016","unstructured":"Coffman, C. J., Edelman, D. & Woolson, R. F. To condition or not condition? Analysing \u2018change\u2019 in longitudinal randomised controlled trials. BMJ Open 6, e013096 (2016).","journal-title":"BMJ Open"},{"key":"2576_CR52","doi-asserted-by":"crossref","unstructured":"Twisk, J. W. R. Analysis of Data from Randomized Controlled Trials: a Practical Guide Chap. 3 (Springer, 2021).","DOI":"10.1007\/978-3-030-81865-4"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02576-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02576-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02576-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T23:34:34Z","timestamp":1730244874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02576-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2576"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02576-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.H. is a shareholder and member of the board of Vactech Ltd, which develops vaccines against picornaviruses. N.L. and J.W. are employees of Apodemus\/Curovir AB, which own the rights to the commercialization of the results of this trial. Curovir AB is developing antiviral drugs for enterovirus-induced diseases. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}